Pharmaceuticals, Biotechnology & Life Sciences

Insmed Inc. (NASDAQ: INS) briefly appears in a market note on Invesco QQQ Trust ETF, showing a modest share rise amid neutral investor sentiment and broader geopolitical focus.

Vertex Pharmaceuticals’ March 2026 insider sale under Rule 144 shows disciplined share management, no impact on liquidity, and highlights the company’s transparent governance amid a competitive biopharma market.

Read how Sandoz Group AG’s March 2026 bond and credit deals cut debt costs, extend maturities, and fuel growth in generics and biosimilars.

Discover how Eisai’s lecanemab presentation at AD/PD 2026 will shape Alzheimer’s treatment—clinical breakthroughs, reimbursement insights, and market strategy revealed.

Haleon PLC’s £65 m Shanghai plant targets China’s tier‑two/three oral‑health boom, using clinical differentiation and local R&D to boost margins and market reach.

Swiss market dips amid rising oil prices and geopolitical tension, showing how Novartis and other pharma firms face cost‑pressure, competition, and cross‑border partnership risks.

Neurocrine Biosciences will host a live investor webinar on March 17, revealing CNS‑forum insights, pipeline progress, and strategic partnerships for neurological & endocrine therapies.

Biogen’s latest update reveals promising Phase 1b results for salanersen in spinal muscular atrophy, outlining a Phase 3 plan to evaluate safety, efficacy, and combination therapy while navigating accelerated regulatory pathways.

Explore TecDAX’s latest tech‑index moves: solar, semiconductors, and AI health tools—plus breakthrough CRISPR, mRNA, and microneedle therapies shaping future investments.

Explore Bayer AG’s market stance—steady yet flat in a volatile German market, with growth plateaued but green chemistry and digital health offering new prospects.